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ISSUE @ A GLANCE
Atrial fibrillation: still an issue
Thomas F. Lu¨scher
Editor-in-Chief, Zurich Heart House, Careum Campus, Moussonstrasse 4, 8091 Zurich, Switzerland
Atrial fibrillation is undoubtedly a clinically important condition.
While is it steadily increasing in prevalence and incidence in
ageing Western societies, management has become more effective
and complex,1 involving drugs2,3 and interventions5,6 (figure 1 from
Haegeli and Calkins4).
In this issue, important novel evidence is provided to our readers.
The first paper by Michael Ezekowitz from the Sidney Kimell Medical
College, Broomall, PA, USA entitled ‘Rivaroxaban vs. vitamin K
antagonists for cardioversion in atrial fibrillation’7 is an ESC
FAST TRACK paper presented at the Hotline Session in Barcelona
at the ESC’s Annual Congress 2014. The X-VeRT trial randomly
compared rivaroxaban (20 or 15 mg/day with renal failure) or
dose-adjusted vitamin K antagonists (VKAs) in 1504 patients with
atrial fibrillation (AF) undergoing elective cardioversion. The
primaryefficacyoutcomewas stroke, transient ischaemic attack, per-
ipheral embolism, myocardial infarction, and cardiovascular death,
while the safety outcome was major bleeding. The authors found
that oral rivaroxaban was as effective and safe as VKAs. This is a
clinically important finding, which will affect daily practice of many
cardiologists.
The second paper by Stine Darkner et al. from the Copenhagen
University Hospital ‘Recurrence of arrhythmia following
short-term oral AMIOdarone after CATheter ablation for
atrial fibrillation: a double-blind, randomized, placebo-
controlled study (AMIO-CAT trial)’8 is another ESC FAST
TRACK paper from Barcelona accompanied by a thought-provoking
Editorial by Karl-Heinz Kuck,9 current president of the ESC Heart
Rhythm Association. The clinical background of this study is that
patients undergoing catheter ablation forAFoften experience recur-
rent arrhythmias afterwards. The authors investigated whether or
not short-termuseof amiodaronepreventsearlyarrhythmias follow-
ing radiofrequency ablation. Contrary to the expectations of many,
they found that short-term amiodarone treatment following ablation
for AF did not reduce the recurrence of atrial tachyarrhythmias at
6 months. However, it more than halved atrial arrhythmia-related
hospitalization and cardioversion rates during that period. Thus,
the use of amiodarone may still have some clinical value.
In a third paper, Gregory Y.H. Lip from the University of Birming-
ham, UK reports on the ‘Prognosis and treatment of atrial
fibrillation patients by European cardiologists: 1-year
follow-up of the EURObservational Research Programme-
Atrial Fibrillation General Registry Pilot Phase (EORP-AF
Pilot registry)’,10 another ESC FASTTRACKmanuscript fromBarce-
lona, accompanied by anEditorial by Jayasree Pillarisetti.11 The ESC
EURObservational Research Programme (EORP), currently led by
Roberto Ferrari, is an important initiative of the ESC. In this case,
the EORP focused on the management of AF in 3119 patients
from nine member countries. In the current 1-year follow-up,
the authors provide data obtained since the publication of the
new ESC Guidelines on AF. Overall oral anticoagulant (OAC) use
remains high, although persistence with therapy appears to be a
problem. Nonetheless, continued OAC use was more common
than in previous reports. Despite the high prescription of OAC,
1-year mortality and morbidity remained high in AF, particularly
from heart failure and hospitalizations. This report thus suggests
that ESCGuidelines, in this case onAF, do impact on clinical practice,
although improvements in guideline implementation remain an issue.
In a last paper, Gu¨nter Breithardt et al. from the University of
Mu¨nster analysed a subgroup of the Rocket-AF trial in their study
on the ‘Clinical characteristics and outcomes with rivaroxa-
ban vs. warfarin in patients with non-valvular atrial fibrilla-
tion but underlying native mitral and aortic valve disease
participating in the ROCKET AF trial’.12 This manuscript is
accompanied by an Editorial by Stefan Hohnloser from the
Wolfgang-Goethe-University of Frankfurt.13 The authors investi-
gated clinical characteristics and outcomes of patients with valvular
disease in the ROCKET AF trial. The results suggest that many
patients classified as having ‘non-valvular AF’ have significant valvular
Figure 1 Three-dimensional electroanatomical map of the left
atrium and the pulmonary vein ostia in a posterior projection
with circumferential ablation lesions (red points) around ipsilateral
pulmonary veins (from Haegeli and Calkins).4
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disease. Their riskof strokewas similar to thatof patientswithout this
condition. Of note, the efficacy of rivaroxaban was similar in patients
with and without significant valvular disease as compared with war-
farin. Surprisingly, the risk of bleeding was higher with rivaroxaban
in patients with valvular disease, but was the same as compared
with warfarin among those without this condition. Importantly, AF
patients with and without valvular disease experienced the same
stroke-preventive benefit of OACs.
In aCURRENTOPINION article entitled ‘What is ‘valvular’ atrial
fibrillation?Areappraisal’, complementing to the contribution of
Breithardt et al., John Camm from St. George’s University of London
discusses the guidelines for themanagement of patientswith AF.6 He
stresses the fact that patients at thrombo-embolic risk with non-
valvular AF can now be managed either with a VKA or with novel
oral anticoagulants (NOACs), while patients with valvular AF have
been restricted to VKAs. Valvular AF has included any valvular dis-
order, including valve replacement and repair. Such patients have
not been included in NOAC trials, but there is also no stringent
argument to exclude them. Conversely, in patients with mechanical
valves, dabigatran etexilate against VKA treatment was stopped,
because of increased rates of thrombo-embolism and bleeding.
Patients with AF and bioprostheses, native aortic valve disease,
mitral regurgitation, and mitral valve repair were variously included,
and analyses do not suggest that they respond differently from
others. Camm et al. thus propose that the equivocal term ‘valvular
AF’ be replaced with the specific terminology of ‘mechanical and
rheumatic mitral valvular AF’.
The issue also contains a clinical review by Peter Ju¨ni et al. from the
University of Bern, Switzerland on ‘Systematic reviews and
meta-analyses: principles and pitfalls’, an issue all cardiologists,
particularly those involved in clinical research, should be aware of.14
Indeed, systematic reviews andmeta-analyses allow for amore trans-
parentandobjective appraisalof theevidence.However, theirmisuse
may lead to misleading results. In their review, the authors discuss
the main steps that should be taken when conducting systematic
reviews and meta-analyses, namely the preparation of a review
protocol, identification of eligible trials and data extraction, pooling
of treatment effects across trials, investigation of potential reasons
for differences in treatment effects across trials, and complete
reporting of the review conduct and findings. They conclude that,
if conducted and reported properly, systematic reviews and meta-
analyses will increase our understanding of the strengths and weak-
nesses of available evidence, which may eventually facilitate clinical
decision-making.
We sincerely hope that this issue of the European Heart Journalwill
also be of interest to our esteemed readers.
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